A personalized approach to optimize hepatitis B treatment in treatment-naive patients

2010 ◽  
Vol 15 (Suppl 3) ◽  
pp. 53-59 ◽  
Author(s):  
Patrick Marcellin ◽  
Jake Liang
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Treatment ◽  
Treatment Naïve ◽  
Personalized Approach

scholarly journals Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

2014 ◽  
Vol 13 (3) ◽  
pp. 327-336 ◽  
Author(s):  
Ezequiel Ridruejo ◽  
Sebastián Marciano ◽  
Omar Galdame ◽  
María V. Reggiardo ◽  
Alberto E. Muñoz ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Clinical Practice ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Efficacy And Safety ◽  
Hepatitis B Treatment ◽  
Treatment Naïve

scholarly journals Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ming-Ying Lu ◽  
Chun-Ting Chen ◽  
Yu-Lueng Shih ◽  
Pei-Chien Tsai ◽  
Meng-Hsuan Hsieh ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Drug Users ◽  
High Risk Group ◽  
Health Concern ◽  
Hepatitis D ◽  
Hcv Genotypes ◽  
Hbsag Carriers ◽  
Treatment Naïve ◽  
Hdv Infection ◽  
Hbsag Seropositivity

AbstractThe spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67.0%) of 1697 prisoners. 89.2% of participants were IDUs and none had HIV infection. The prevalence of HBsAg, anti-HCV, dual HBsAg/anti-HCV, HBsAg/anti-HDV, and triple HBsAg/anti-HCV/anti-HDV was 13.6%, 34.8%, 4.9%, 3.4%, and 2.8%, respectively. HBV viremia rate was significantly lower in HBV/HCV-coinfected than HBV mono-infected subjects (66.1% versus 89.9%, adjusted odds ratio/95% confidence intervals [aOR/CI] = 0.27/0.10–0.73). 47.5% anti-HCV-seropositive subjects (n = 396) were non-viremic, including 23.2% subjects were antivirals-induced. The predominant HCV genotypes were genotype 6(40.9%), 1a(24.0%) and 3(11.1%). HBsAg seropositivity was negatively correlated with HCV viremia among the treatment naïve HCV subjects (44.7% versus 72.4%, aOR/CI = 0.27/0.13–0.58). Anti-HCV seropositivity significantly increased the risk of anti-HDV-seropositivity among HBsAg carriers (57.1% versus 7.1%, aOR/CI = 15.73/6.04–40.96). In conclusion, IUDs remain as reservoirs for multiple hepatitis viruses infection among HIV-uninfected prisoners in Taiwan. HCV infection increased the risk of HDV infection but suppressed HBV replication in HBsAg carriers. An effective strategy is mandatory to control the epidemic in this high-risk group.

Autonomic impairment in treatment-naive patients with chronic hepatitis B and C infections

2021 ◽  
pp. 102928
Author(s):  
Chih-Cheng Huang ◽  
Keng-Liang Wu ◽  
Jia-Shou Liu ◽  
Yung-Yee Chang
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Treatment Naïve

scholarly journals DNA-guided hepatitis B treatment, viral load is essential, but not sufficient

2009 ◽  
Vol 15 (4) ◽  
pp. 423 ◽  
Author(s):  
Rafael Bárcena Marugán ◽  
Silvia García Garzóno
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Hepatitis B Treatment

scholarly journals Na+-Taurocholate Co-Transporting Polypeptide (NTCP) in Livers, Function, Expression Regulation, and Potential in Hepatitis B Treatment

Livers ◽  
2021 ◽  
Vol 1 (4) ◽  
pp. 236-249
Author(s):  
Xiaoyu Zhao ◽  
Waqas Iqbal ◽  
Pingnan Sun ◽  
Xiaoling Zhou
Keyword(s):  
Hepatitis B ◽  
Hepatoma Cell ◽  
Sodium Taurocholate ◽  
Hbv Infection ◽  
Viral Receptor ◽  
Hepatitis D ◽  
Hepatoma Cell Lines ◽  
Chronic Hepatitis B Virus ◽  
Hepatitis B Treatment

Chronic hepatitis B virus (HBV) infection has become one of the leading causes of liver cirrhosis and hepatocellular carcinoma globally. The discovery of sodium taurocholate co-transporting polypeptide (NTCP), a solute carrier, as a key receptor for HBV and hepatitis D virus (HDV) has opened new avenues for HBV treatment. Additionally, it has led researchers to generate hepatoma cell lines (including HepG2-NTCP and Huh-7-NTCP) susceptible to HBV infection in vitro, hence, paving the way to develop and efficiently screen new and novel anti-HBV drugs. This review summarizes the history, function and critical findings regarding NTCP as a viral receptor for HBV/HDV, and it also discusses recently developed drugs targeting NTCP.

scholarly journals Achieving a Cure: The Next Frontier in Hepatitis B Treatment

Liver Cancer ◽  
2021 ◽  
pp. 109-126
Author(s):  
Tina Boortalary ◽  
Brianna Shinn ◽  
Dina Halegoua-DeMarzio ◽  
Hie-Won Hann
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Treatment
Sign in / Sign up

Export Citation Format

Share Document